Drug Trial Radar · NCT04718961
A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)
Last checked: Nov 19, 2026Latest source record: Aug 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
4
Actual
Start
Jan 4, 2021
Primary completion
Dec 7, 2022
Study completion Dec 7, 2022
Sponsor
- Lead sponsor
- Mirum Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 22, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Part 1 is an open-label randomized study of volixibat in patients with Intrahepatic Cholestasis of Pregnancy (ICP) and elevated serum bile acid concentrations (sBA) to evaluate safety and tolerability of two doses of volixibat. Part 2 is a double-blind, placebo controlled, study designed to evaluate the safety and efficacy of a selected volixibat dose.
Conditions
- Intrahepatic Cholestasis of Pregnancy
Interventions
VolixibatDrug
Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.
PlaceboDrug
Capsules matched to study drug minus active substance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Assess the Safety and Tolerability of Volixibat in Participants With ICPTime frame: Through to end of treatment, up to 21 weeks
Locations
20 sites in 3 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
Yale School of Medicine
New Haven, Connecticut
University of Miami
Miami, Florida
The Ohio State University Wexner Medical Center
Columbus, Ohio
The University of Texas Medical Branch - Galveston
Galveston, Texas
University of Texas Health Science Center
Houston, Texas
University of Texas Health Science Center at San Antonio
San Antonio, Texas
Christchurch Women's Hospital
Christchurch, New Zealand
Capital & Coast District Health Board, Wellington Regional Hospital
Wellington, New Zealand
Dunedin Hospital
Dunedin, Otago, New Zealand
Birmingham Womens and Childrens NHS Foundation Trust
Birmingham, United Kingdom
University Hospital of Wales
Cardiff, United Kingdom
St Richard's Hospital
Chichester, United Kingdom
Barts Health NHS Trust- Whipps Cross University Hospital
London, United Kingdom
Royal Free London Hospital NHS Foundation Trust
London, United Kingdom
Guy's and St Thomas' NHS Foundation Trust
London, United Kingdom
West Middlesex University Hospital
Middlesex, United Kingdom
The Newcastle upon Tyne Hospitals NHS Foundation Trust
Newcastle upon Tyne, United Kingdom
Medway NHS Foundation Trust
Gillingham, Kent, United Kingdom
Bradford Royal Infirmary
Bradford, West Yorkshire, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.